Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Lancet
; 399(10336): 1718-1729, 2022 04 30.
Article
in En
| MEDLINE
| ID: mdl-35367007
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Testicular Neoplasms
/
COVID-19
/
Melanoma
Type of study:
Clinical_trials
Limits:
Child
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2022
Type:
Article